Skip to content
HowShorted

COLLEGIUM PHARMACEUTICAL, INC short interest in 2023

In 2023, COLLEGIUM PHARMACEUTICAL, INC's disclosed short interest ran from 11.82% of shares outstanding on 13 Jan 2023 to 19.56% on 29 Dec 2023, a change of +7.74 percentage points. The year's high was 22.01% on 15 Aug 2023 and its low 11.57% on 31 Jan 2023, averaging 18.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 34.49 days on 14 Jul 2023. Full history: COLLEGIUM PHARMACEUTICAL, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for COLLEGIUM PHARMACEUTICAL, INC in 2023

2023 in figures

Start of year
11.82% (13 Jan 2023)
End of year
19.56% (29 Dec 2023)
Change
+7.74 pp
High
22.01% (15 Aug 2023)
Low
11.57% (31 Jan 2023)
Average
18.10%
Highest days to cover
34.49 (14 Jul 2023)
SEC filings marked
9

Every report in 2023

COLLEGIUM PHARMACEUTICAL, INC short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202311.82%5.98
31 Jan 202311.57%13.14
15 Feb 202313.83%5.21results (8-K)
28 Feb 202316.05%12.0410-K filed, results (8-K)
15 Mar 202316.74%15.04
31 Mar 202317.10%19.18
14 Apr 202318.16%16.25
28 Apr 202318.29%22.38
15 May 202318.39%14.1210-Q filed, results (8-K)
31 May 202318.16%25.91
15 Jun 202318.90%20.24
30 Jun 202319.28%17.82
14 Jul 202319.00%34.49
31 Jul 202317.09%24.93
15 Aug 202322.01%15.6910-Q filed, results (8-K)
31 Aug 202321.32%28.15
15 Sep 202319.91%22.22
29 Sep 202318.62%28.10
13 Oct 202318.66%23.86
31 Oct 202318.44%23.78
15 Nov 202320.86%17.3110-Q filed, results (8-K)
30 Nov 202320.25%18.61
15 Dec 202320.29%15.07
29 Dec 202319.56%14.72

See also: COLLEGIUM PHARMACEUTICAL, INC's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.